Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo’s One-Dose Version Of GSK’s Relenza Rivals Tamiflu

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo's one-dose version of GlaxoSmithKline's Relenza (zanamivir) flu drug has shown in trials to be just as effective as the two-dose regimen for Roche Holding's Tamiflu (oseltamivir), according to a study. Daiichi Sankyo plans to begin Phase III studies for its drug in several countries this coming winter. The usual regimen for the two major flu drugs has been twice a day for five days. Daiichi has given its drug the temporary name of CS-8958, in the same class as the other two drugs for preventing the spread of flu viruses beyond the infected cell. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel